<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499367</url>
  </required_header>
  <id_info>
    <org_study_id>N15TON</org_study_id>
    <nct_id>NCT02499367</nct_id>
  </id_info>
  <brief_title>Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients</brief_title>
  <acronym>TONIC</acronym>
  <official_title>Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center non-blinded randomized non-comparative phase II trial. The first&#xD;
      stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1&#xD;
      with no induction treatment before nivolumab).&#xD;
&#xD;
      For the second stage, the number of arms will be reduced based on the results obtained in the&#xD;
      first stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple negative breast cancer (TNBC) patients have a relatively high relapse rate and upon&#xD;
      relapse the median overall survival is less than a year. No targeted therapies are currently&#xD;
      available for this subgroup. Compared to other breast cancer subtypes, the percentage of&#xD;
      tumor-infiltrating lymphocytes (TILs) is significantly higher in TNBC. Given the durable&#xD;
      responses induced by the immune checkpoint inhibitor nivolumab in other advanced solid&#xD;
      cancers, immunotherapeutic approaches, such as blockade of PD-1 by nivolumab may be the key&#xD;
      to treat TNBC. Moreover, since classical anticancer agents can stimulate immune effector&#xD;
      cells, the investigators hypothesize that short-term induction treatment with radiation,&#xD;
      doxorubicin, cyclophosphamide or cisplatin induces an anticancer immune response resulting in&#xD;
      synergistic activity with nivolumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>assessed monthly until progression; median 12 months</time_frame>
    <description>Time from randomization todate of first tumor progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At 12 weeks and 6 months</time_frame>
    <description>complete response or partial response at 12 weeks and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>At 6 months</time_frame>
    <description>Beneficial response (complete response, partial response or stable disease) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of all study regimens</measure>
    <time_frame>assessed until 100 days after of treatment end</time_frame>
    <description>adverse events will be graded according to NCI Common Toxicity Criteria v 4.0</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy on metastatic lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15mg flat dose, once weekly for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metronomic schedule, 50mg daily orally for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg/m2, weekly for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No induction treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 3 mg/kg, every 2 weeks after induction treatment</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
    <arm_group_label>No induction treatment</arm_group_label>
    <arm_group_label>Radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>20 Gy to metastatic lesion</description>
    <arm_group_label>Radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose doxorubicin</intervention_name>
    <description>15 mg flat dose, once weekly for 2 weeks</description>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>metronomic schedule, 50 mg daily orally for 2 weeks</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg/m2, weekly for 2 weeks</description>
    <arm_group_label>Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic triple negative breast cancer with confirmation of Estrogen Receptor (ER)&#xD;
             and HER2 negativity on a histological biopsy of a metastatic lesion&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Metastatic lesion accessible for histological biopsy (Mandatory biopsies:&#xD;
             pre-induction treatment, post-induction treatment, 6-weeks. Optional biopsies:&#xD;
             12-weeks, at progression, of irradiated site). The pre-induction treatment biopsy has&#xD;
             to contain sufficient tumor content (â‰¥100 tumor cells); subjects with samples that&#xD;
             have insufficient tumor content will require re-biopsy prior to induction treatment.&#xD;
             Interval between last treatment and pre-induction biopsy has to be at least 14 days&#xD;
&#xD;
          -  One, two or three line(s) of chemotherapy for metastatic disease and with progression&#xD;
             of disease on last treatment regimen&#xD;
&#xD;
          -  Evaluable disease according to RECIST 1.1&#xD;
&#xD;
          -  Metastatic lesion accessible for radiation with 1x20 Gray or 3x8 Gray&#xD;
&#xD;
          -  Subjects with brain metastases are eligible if these are not symptomatic. Subjects who&#xD;
             received prior treatment for brain metastases should be free of progression on&#xD;
             magnetic resonance imaging (MRI) for at least 4 weeks after treatment is completed and&#xD;
             prior to first dose of study drug administration. There must also be no requirement&#xD;
             for immunosuppressive doses of systemic corticosteroids (&gt; 10 mg/day prednisone&#xD;
             equivalents) for at least 2 weeks prior to study drug administration.&#xD;
&#xD;
          -  WHO performance status of 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris.&#xD;
&#xD;
          -  known history of leptomeningeal disease localization&#xD;
&#xD;
          -  history of having received other anticancer therapies within 2 weeks of start of the&#xD;
             study drug&#xD;
&#xD;
          -  history of immunodeficiency, autoimmune disease, conditions requiring&#xD;
             immunosuppression (&gt;10 mgl daily prednisone equivalents) or chronic infections.&#xD;
&#xD;
          -  prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody&#xD;
&#xD;
          -  live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          -  active other cancer&#xD;
&#xD;
          -  positive test for hepatitis B surface virus surface antigen (HBsAg) or hepatitis&#xD;
&#xD;
          -  history of uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  current pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple negative</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

